Logo
Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome to ShareScene - Talk Shares And Take Stock With Australia's Sharemarket Community - New Here? Click To Register >

758 Pages (Click to Jump) V  < 1 2 3 4 5 6 > »    
 
  
Reply to this topic

BLT, BENITEC BIOPHARMA LIMITED
rubra
post Posted: Mar 16 2015, 06:13 PM
  Quote Post


Posts: 118
Thanks: 36


In Reply To: Pannobhaso's post @ Mar 13 2015, 01:39 PM

very interesting link posted for trial

Estimated Primary Completion Date: June 2031

that is a very long wait

 
plastic
post Posted: Mar 13 2015, 06:25 PM
  Quote Post


Posts: 6,227
Thanks: 208


AuntyM on IV found this piece. What I like about it is it basically confirms all of my assertions about ssRNAi. In effect, it means antisense is the bomb.

QUOTE
http://online.liebertpub.com/doi/abs/10.1089/nat.2014.0527 (1 author from Isis).
Single-stranded silencing RNAs (ss-siRNAs) are chemically modified single-stranded oligonucleotides that can function through the cellular RNA interference (RNAi) machinery to modulate gene expression. Because their invention is recent, few studies have appeared describing their use and the potential of ss-siRNAs as a platform for controlling gene expression remains largely unknown. Using oligonucleotides to modulate splicing is an important area for therapeutic development and we tested the hypothesis that ss-siRNAs targeting splice sites might also be capable of directing increased production of therapeutically promising protein isoforms. Here we observe that ss-siRNAs alter splicing of dystrophin. Altered splicing requires a seed sequence complementarity to the target and expression of the RNAi factor argonaute 2. These results demonstrate that ss-siRNAs can be used to modulate splicing, providing another option for therapeutic development programs that aim to increase production of key protein isoforms. Splicing is a classical nuclear process and our data showing that it can be modulated through the action of RNA and RNAi factors offers further evidence that RNAi can take place in mammalian cell nuclei.







--------------------
Where are the Americans?
 
plastic
post Posted: Mar 13 2015, 03:54 PM
  Quote Post


Posts: 6,227
Thanks: 208


Question for drafter, how is BLT identifying it's targets?

From HC:

QUOTE
Calimmune and Gradalis programmes are great but BLT has dibs on the best commercial targets thanks to the power of its IP.







--------------------
Where are the Americans?
 
Pannobhaso
post Posted: Mar 13 2015, 01:39 PM
  Quote Post


Posts: 505
Thanks: 335


The City of Hope is starting a third clinical trial using ddRNAi to treat AIDS/lymphoma patients. This follows on the work done with Benitec in the first clinical trial back in 2010. The new trial will begin recruiting next month.
https://clinicaltrials.gov/ct2/show/NCT0233...15&lup_d=30

In summary, there are now two ddRNAi HIV trials being conducted by the City of Hope; there is one trial being conducted by the Fred Hutchinson Cancer Research Center; there is one trial being conducted by Calimmune - with a second trial to start in Australia later this year; UC Davis is waiting for funding before starting an FDA approved trial and Prof Berkhout's team in the Netherlands is also seeking funding.



--------------------
"It turns out Pannobhaso is right."
Plastic (Alias rubra)

Said 'Thanks' for this post: wasabibarako  
 
plastic
post Posted: Mar 12 2015, 07:23 PM
  Quote Post


Posts: 6,227
Thanks: 208


It seems odd this cap. raising GTG is undertaking is so structured and precise. 10AM New York time they will announce closing of a placement after having already announced the allotment and details of the transaction. They have never done anything like this before.

What's the big deal?

The placement is a nasty one for existing holders.

Considering the TPP talks are underway atm, ARWR closing with Novartis last week could be a curtain raiser for something, tomorrow is Friday, strong upwards pressure in the market today I wonder if tomorrow is the day the malingering Americans make an appearance and put this dog down for a "significant" premium. I doubt it. More like we see RA Capital put in an appearance at GTG. If they do, the lesson to be learned is they have no love for bagholders.

http://www.asx.com.au/asxpdf/20150311/pdf/42x6gdtmg58gl3.pdf






--------------------
Where are the Americans?
 
Pannobhaso
post Posted: Mar 10 2015, 08:24 PM
  Quote Post


Posts: 505
Thanks: 335


In Reply To: plastic's post @ Mar 10 2015, 03:37 PM

It is clear that the Mad Hatter is at his old tricks again. He continues to make 2+2=1. Everyone knows that the cross licensing options are for AGREED targets. In other words, Benitec would have to approve any target that Alnylam wanted to use. But why would Alnylam bother? They are fairly and squarely at the forefront of siRNA, despite what the Mad Hatter would have one believe, and have enough pipeline products to keep them going for quite some time.

It makes me wonder why the Mad Hatter keeps posting here. He does not know the difference between siRNA and shRNA, or the difference between mRNA and miRNA. He does not understand about biotech patents or the biotech industry. Pity the fellow who reads his nonsense and is fooled by it.



--------------------
"It turns out Pannobhaso is right."
Plastic (Alias rubra)

Said 'Thanks' for this post: wasabibarako  
 


plastic
post Posted: Mar 10 2015, 07:10 PM
  Quote Post


Posts: 6,227
Thanks: 208


On re-reading that passage again, it is clear America is still having a Sputnik moment. Albeit in a Made in China yoke.



--------------------
Where are the Americans?
 
plastic
post Posted: Mar 10 2015, 04:10 PM
  Quote Post


Posts: 6,227
Thanks: 208


So this is what we are waiting for: Assurances that there will be no double cross.

Not hard to figure out why America has an obesity epidemic when they move at these speeds.

QUOTE
He said while the recommitment to TPP completion by the twelve leaders in Beijing is "an important demonstration of political will", the dragging TPP talks will only achieve a breakthrough once President Obama receives the Trade Promotion Authority from Congress that "would allow it to conclude an agreement without having to subject the final text to possible Congressional amendments".


http://usa.chinadaily.com.cn/us/2015-03/09...nt_19761816.htm



--------------------
Where are the Americans?
 
plastic
post Posted: Mar 10 2015, 03:37 PM
  Quote Post


Posts: 6,227
Thanks: 208


QUOTE
The only ddRNAi IP that is owned by Alynlam is that which it obtained from Nucleonics and the court has ruled that BLT's IP takes precedence over this. In terms of siRNA patents and who owns what, anyone prepared to check the patents will see the order of precedence and will note that Alnylam figures pretty prominently in that order - either through ownership or licensing.


So the contra-options don't count according to Pinocchio's skewed logic because they're not "owned". Whatever that means in the context of exclusive licences.

According to Stanley Crooke its all anti-sense anyway. And we know ISIS is the boss in that regard. That's why ALNY had to pay the vig up to the man when Monsanto licenced with them.

What we don't know though, which is what Pinocchio will never admit to, is which patents are covered by the Patent Secrecy Act and the details of those disclosures that are sealed under CT orders.

I sure would like to know the shape of the patent landscape at that area of RISC. That's the area BLT needs access to or they are completely gone for all money.

This is the article I forgot to append.

http://www.xconomy.com/wisconsin/2015/03/0...ingle_page=true






--------------------
Where are the Americans?
 
Pannobhaso
post Posted: Mar 10 2015, 11:59 AM
  Quote Post


Posts: 505
Thanks: 335


In Reply To: plastic's post @ Mar 10 2015, 04:30 AM

The only ddRNAi IP that is owned by Alynlam is that which it obtained from Nucleonics and the court has ruled that BLT's IP takes precedence over this. In terms of siRNA patents and who owns what, anyone prepared to check the patents will see the order of precedence and will note that Alnylam figures pretty prominently in that order - either through ownership or licensing.





--------------------
"It turns out Pannobhaso is right."
Plastic (Alias rubra)
 
 


758 Pages (Click to Jump) V  < 1 2 3 4 5 6 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareScene.com, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING